RA Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

RA Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,131,775	Closed	-$19.4M	–	58
2023 Q1	$19.4M	Sell	1,131,775 -1,275,374	-53%	-$25M	0.44%	46
2022 Q4	$47.1M	Buy	2,407,149 +300,000	+14%	+$5.52M	0.96%	33
2022 Q3	$33.6M	Hold	2,107,149	–	–	0.72%	43
2022 Q2	$29M	Hold	2,107,149	–	–	0.77%	38
2022 Q1	$33.4M	Hold	2,107,149	–	–	0.73%	42
2021 Q4	$46M	Hold	2,107,149	–	–	0.81%	36
2021 Q3	$63M	Hold	2,107,149	–	–	0.87%	34
2021 Q2	$93.3M	Hold	2,107,149	–	–	1.5%	18
2021 Q1	$93.5M	Sell	2,107,149 -28,932	-1%	-$1.59M	1.41%	20
2020 Q4	$117M	Buy	+2,136,081	New	+$77.9M	1.64%	17

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RA Capital Management's RCKT Position: Q2 2023 in Review

RA Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2023, closing a stake of 1,131,775 shares — an estimated $19.4M sold.

RA Capital Management first reported a position in RCKT in Q4 2020 and held it in 10 quarters. The position peaked at $117M in Q4 2020. 164 funds tracked by Wall St. Rank hold RCKT as of Q2 2023.

RA Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
RA Capital Management sold 1,131,775 Rocket Pharmaceuticals shares in Q2 2023, an estimated $19.4M.
RA Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 10 quarters.
RA Capital Management's Rocket Pharmaceuticals position peaked at $117M in Q4 2020.
164 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2023.

Based on RA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.